Most Americans unaware of cancer risks associated with drinking...
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just...
New biomarker may guide best use of KRAS inhibitors in lung...
Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor,...
ASCO: MD Anderson’s Christopher Flowers honored for...
Christopher Flowers, M.D., division head of Cancer Medicine and chair of Lymphoma/Myeloma at The University of Texas MD Anderson...
CPRIT awards over $21 million to MD Anderson for cancer...
The University of Texas MD Anderson Cancer Center today was awarded $21.4 million from the Cancer Prevention and Research Institute of...
UT MD Anderson and Texas Children’s Hospital announce $150...
The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital today announced a $150 million gift from Kinder...
AACR: New CAR T cell therapy benefits patients with...
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting...
AACR: HER2 targeted therapy shows promise in previously...
Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.
...
...
AACR: Topical gel relieves painful skin rash side effect...
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality...
AACR: First-in-class covalent Werner helicase inhibitor...
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
Drug works similarly to other...